Expert Ratings For Tandem Diabetes Care
Portfolio Pulse from Benzinga Insights
11 analysts have evaluated Tandem Diabetes Care (NASDAQ:TNDM) over the past three months, showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target has increased to $43.82, reflecting a 32.43% rise from the previous target. Analysts have raised their ratings and price targets, indicating positive sentiment towards the company's future performance.
May 22, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown a mix of bullish and somewhat bullish perspectives on Tandem Diabetes Care (NASDAQ:TNDM) over the past three months. The average 12-month price target has increased to $43.82, reflecting a 32.43% rise from the previous target. Analysts have raised their ratings and price targets, indicating positive sentiment towards the company's future performance.
The increase in average price target and the majority of analysts raising their ratings indicate a positive short-term outlook for TNDM. The upward trend in price targets suggests that analysts expect the company's stock to perform well in the near future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100